Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: A case series

European Journal of Neurology

Volumn 20, Issue 9, 2013, Pages 1241-1246

  Dostal, M ^a   Weber Schoendorfer, C ^a   Sobesky, J ^a   Schaefer, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fetal outcome; Levodopa; Pramipexole; Pregnancy; Restless legs syndrome; Ropinirole; Rotigotine

Indexed keywords

BENSERAZIDE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ARTICLE; BIRTH DEFECT; DRUG SAFETY; FEMALE; FETOTOXICITY; HUMAN; INDUCED ABORTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MALFORMATION SYNDROME; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY;

FETAL OUTCOME; LEVODOPA; PRAMIPEXOLE; PREGNANCY; RESTLESS LEGS SYNDROME; ROPINIROLE; ROTIGOTINE;

DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; LEVODOPA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84881027202     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12001     Document Type: Article

References (40)

1. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurology 2005; 4: 465-475.
2. Pantaleo NP, Hening WA, Allen RP, Earley CJ. Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep Med 2010; 11: 310-313.
3. Alves DA, Carvalho LB, Morais JF, Prado GF. Restless legs syndrome during pregnancy in Brazilian women. Sleep Med 2010; 11: 1049-1054.
4. Neau JP, Porcheron A, Mathis S, et al. Restless legs syndrome and pregnancy: a questionnaire study in the Poitiers District, France. Eur Neurol 2010; 64: 268-274.
5. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
6. Allain H, tue-Ferrer D, Milon D, Moran P, Jacquemard F, Defawe G. Pregnancy and parkinsonism. A case report without problem. Clin Neuropharmacol 1989; 12: 217-219.
7. Watanabe T, Matsubara S, Baba Y, Tanaka H, Suzuki T, Suzuki M. Successful management of pregnancy in a patient with Segawa disease: case report and literature review. Journal of Obstetrics and Gynaecology Research 2009; 35: 562-564.
8. Sinha A, Hartsilver EL. Anaesthesia for caesarean section in a patient with dopa-responsive dystonia or Segawa's syndrome. Int J Obstet Anesth 2009; 18: 67-72.
9. Ha DE, Legendre G, Colau JC. [Juvenile Parkinson's disease and recurring prematurity. Case report]. Gynecol Obstet Fertil 2007; 35: 224-227.
10. Lindh J. Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine. Mov Disord 2007; 10: 1515.
11. von Graevenitz KS, Shulman LM, Revell SP. Levodopa in pregnancy. Mov Disord 1996; 11: 115-116.
12. Cook DG, Klawans HL. Levodopa during pregnancy. Clin Neuropharmacol 1985; 8: 93-95.
13. Scott M, Chowdhury M. Pregnancy in Parkinson's disease: unique case report and review of the literature. Mov Disord 2005; 20: 1078-1079.
14. Nomoto M, Kaseda S, Iwata S, Osame M, Fukuda T. Levodopa in pregnancy. Mov Disord 1997; 12: 261.
15. De MM, Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy. Mov Disord 2002; 17: 428-429.
16. Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. Mov Disord 2000; 15: 132-135.
17. Ball MC, Sagar HJ. Levodopa in pregnancy. Mov Disord 1995; 10: 115.
18. ito-Leon J, Bermejo F, Porta-Etessam J. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1999; 14: 194.
19. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1998; 13: 34-38.
20. Datta DV, Maheshwari YK, Aggarwal ML. Levodopa in fulminant hepatic failure: preliminary report. Am J Med Sci 1976; 272: 95-99.
21. Chajek T, Berry EM, Friedman G, Abramsky O. Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J 1977; 53: 262-265.
22. Golbe LI. Parkinson's disease and pregnancy. Neurology 1987; 37: 1245-1249.
23. Serikawa T, Shimohata T, Akashi M, et al. Successful twin pregnancy in a patient with parkin-associated autosomal recessive juvenile parkinsonism. BMC Neurology 2011; 11: 72.
24. Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy. Mov Disord 2004; 19: 1114-1115.
25. Einarson A, Choi J, Einarson TR, Koren G. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress Anxiety 2010; 27: 35-38.
26. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29: 555-560.
27. Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; 7: CD000110.
28. Dietz PM, England LJ, Shapiro-Mendoza CK, Tong VT, Farr SL, Callaghan WM. Infant morbidity and mortality attributable to prenatal smoking in the US. Am J Prev Med 2010; 39: 45-52.
29. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006; 194: 921-931.
30. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599-606.
31. Molitch ME. Prolactinomas and pregnancy. Clin Endocrinol 2010; 73: 147-148.
32. Stalldecker G, Mallea-Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010; 13: 345-350.
33. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 2008; 68: 66-71.
34. Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 2010; 73: 236-242.
35. Sharma JB, Roy KK, Mohanraj P, Kumar S, Karmakar D, Barua J. Pregnancy outcome in pituitary tumors. Arch Gynecol Obstet 2009; 280: 401-404.
36. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardia valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol, 2010; 73: 369-374.
37. Valassi E, Klibanski A, Biller BM. Clinical Review: potential cardia valve effects of dopamie agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95: 1025-1033.
38. Herring N, Szimigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 2009; 70: 104-108.
39. Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. Br Med J 2010; 341: c6581.
40. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362: 2185-2193.